Literature DB >> 18928396

Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy.

Carolien J P Van Den Bout-Van Den Beukel1, Lydia Fievez, Meta Michels, Fred C G J Sweep, Ad R M M Hermus, Marjolein E W Bosch, David M Burger, Bert Bravenboer, Peter P Koopmans, André J A M Van Der Ven.   

Abstract

Vitamin D regulates bone metabolism but has also immunoregulatory properties. In HIV-infected patients bone disorders are increasingly observed. Furthermore, low 1,25(OH)(2)D(3) levels have been associated with low CD4(+) counts, immunological hyperactivity, and AIDS progression rates. Few studies have examined the vitamin D status in HIV-infected patients. This study will specifically focus on the effects of antiretroviral agents on vitamin D status. Furthermore, the effect of vitamin D status on CD4 cell recovery after initiation of HAART will be evaluated. Among 252 included patients the prevalence of vitamin D deficiency (<35 nmol/liter from April to September and <25 nmol/liter from October to March) was 29%. Female sex, younger age, dark skin, and NNRTI treatment were significant risk factors in univariate analysis, although in multivariate analyses skin pigmentation remained the only independent risk factor. Median 25(OH)D(3) levels were significantly lower in white NNRTI-treated patients [54.5(27.9-73.8) nmol/liter] compared to white PI-treated patients [77.3 (46.6-100.0) nmol/liter, p = 0.007], while among nonwhites no difference was observed. Both PI- and NNRTI-treated patients had significantly higher blood PTH levels than patients without treatment. Moreover, NNRTI treatment puts patients at risk of elevated PTH levels (>6.5 pmol/liter). Linear regression analysis showed that vitamin D status did not affect CD4 cell recovery after initiation of HAART. In conclusion, 29% of the HIV-1-infected patients had vitamin D deficiency, with skin color as an independent risk factor. NNRTI treatment may add more risk for vitamin D deficiency. Both PI- and NNRTI-treated patients showed higher PTH levels and might therefore be at risk of bone problems. Evaluation of 25(OH)D(3) and PTH levels, especially in NNRTI-treated and dark skinned HIV-1-infected patients, is necessary to detect and treat vitamin D deficiency early.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18928396     DOI: 10.1089/aid.2008.0058

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  65 in total

1.  Vitamin D deficiency in HIV-infected and -uninfected women in the United States.

Authors:  Jigar Chotalia; Maria Frontini; Priyanka Tatini; M Jacques Nsuami; David H Martin; Rebecca A Clark
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

2.  High prevalence of vitamin D deficiency in HIV-infected adults: what are the future research questions?

Authors:  Temitope Oyedele; Oluwatoyin M Adeyemi
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

3.  Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women.

Authors:  E M Stein; M T Yin; D J McMahon; A Shu; C A Zhang; D C Ferris; I Colon; J F Dobkin; S M Hammer; E Shane
Journal:  Osteoporos Int       Date:  2010-06-29       Impact factor: 4.507

4.  Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis.

Authors:  D Nansera; F M Graziano; D J Friedman; M K Bobbs; A N Jones; K E Hansen
Journal:  Int J Tuberc Lung Dis       Date:  2011-11       Impact factor: 2.373

5.  Bone alterations associated with HIV.

Authors:  Amy H Warriner; Michael Mugavero; E Turner Overton
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

6.  Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons.

Authors:  Andy I Choi; Joan C Lo; Kathleen Mulligan; Amanda Schnell; S Craig Kalapus; Yongmei Li; Peter W Hunt; Jeffrey N Martin; Steven G Deeks; Priscilla Y Hsue
Journal:  Clin Infect Dis       Date:  2011-01-27       Impact factor: 9.079

7.  High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial.

Authors:  Virginia A Stallings; Joan I Schall; Mary L Hediger; Babette S Zemel; Florin Tuluc; Kelly A Dougherty; Julia L Samuel; Richard M Rutstein
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

8.  Vitamin D Levels, Natural H1N1 Infection and Response to H1N1 Vaccine among HIV-Infected Individuals.

Authors:  Florence Momplaisir; Ian Frank; Wa Meyer; Deborah Kim; Rosemary Kappes; Pablo Tebas
Journal:  J AIDS Clin Res       Date:  2012-05-20

Review 9.  Vitamin D supplementation and antibacterial immune responses in adolescents and young adults with HIV/AIDS.

Authors:  Rene F Chun; Nancy Q Liu; T Lee; Joan I Schall; Michelle R Denburg; Richard M Rutstein; John S Adams; Babette S Zemel; Virginia A Stallings; Martin Hewison
Journal:  J Steroid Biochem Mol Biol       Date:  2014-08-01       Impact factor: 4.292

10.  Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?

Authors:  Anali Conesa-Botella; Chantal Mathieu; Robert Colebunders; Rodrigo Moreno-Reyes; Evelyne van Etten; Lut Lynen; Luc Kestens
Journal:  AIDS Res Ther       Date:  2009-04-21       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.